Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $43.00 USD
Change Today +1.36 / 3.27%
Volume 1.8M
AKRX On Other Exchanges
As of 8:10 PM 05/1/15 All times are local (Market data is delayed by at least 15 minutes).

akorn inc (AKRX) Snapshot

Previous Close
Day High
Day Low
52 Week High
04/24/15 - $57.10
52 Week Low
05/6/14 - $24.26
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for AKORN INC (AKRX)

akorn inc (AKRX) Related Businessweek News

No Related Businessweek News Found

akorn inc (AKRX) Details

Akorn, Inc. develops, manufactures, and markets generic and branded prescription pharmaceuticals, as well as animal and over-the-counter (OTC) consumer health products in the United States and internationally. It operates through two segments, Prescription Pharmaceuticals and Consumer Health. The Prescription Pharmaceuticals segment markets generic and branded ophthalmics, injectables, oral liquids, otics, topical, inhalants, and nasal sprays. This segment’s generic products include Clobetasol Propionate, a corticosteroid, which is used to treat various skin conditions; Fluticasone Propionate, a corticosteroid used for nasal symptoms of allergic and non-allergic rhinitis conditions; Lidocaine/Prilocaine, a topical anesthetic; Progesterone, which is used to prevent endometrial hyperplasia; Vancomycin, an antibiotic used to treat bacterial infections; and other products. The Consumer Health segment markets branded and private label animal health products, as well as OTC products for the treatment of dry eye under the TheraTears brand name. This segment’s branded products comprise Akten, a topical ocular anesthetic gel; AzaSite, an antibiotic used to treat bacterial conjunctivitis; Cosopt, Cosopt PF, Betimol, and Zioptan, which are used in the treatment of glaucoma; Nembutal, a sedative; and Xopenex inhalation solution for the treatment or prevention of bronchospasm. It also markets other OTC consumer health products, including Mag-Ox, a diabetes magnesium supplement, and the Zostrix brand of capsaicin products for pain management; and animal health branded and generic products comprising Anased, Tolazine, Yobine, Butorphic, and VetaKet. Akorn, Inc. was founded in 1971 and is headquartered in Lake Forest, Illinois.

1,644 Employees
Last Reported Date: 03/17/15
Founded in 1971

akorn inc (AKRX) Top Compensated Officers

Chief Executive Officer
Total Annual Compensation: $1.1M
Chief Financial Officer and Principal Account...
Total Annual Compensation: $384.0K
Chief Operating Officer
Total Annual Compensation: $423.6K
Senior Vice President, General Counsel and Se...
Total Annual Compensation: $349.1K
Senior Vice President of National Accounts an...
Total Annual Compensation: $288.4K
Compensation as of Fiscal Year 2014.

akorn inc (AKRX) Key Developments

Akorn, Inc. Announces Executive Appointments

Akorn, Inc. announced the executive appointments for roles on the company management team. Jonathan Kafer, former Vice President, Account Management at Allergan, Inc., was appointed Executive Vice President, Sales and Marketing. In this newly-created role, Mr. Kafer will oversee all commercial functions for all of Akorn's business units. Mr. Kafer will also play an integral role in strategic market and product portfolio considerations. Randall Pollard was appointed Vice President and Corporate Controller. In this role, Mr. Pollard will oversee all accounting and financial reporting functions within Akorn. Mr. Pollard joins Akorn from Novartis Pharmaceuticals, where he most recently served as the head of accounting and reporting for Novartis' generic division, Sandoz. Steve Lichterwas appointed Executive Vice President, Pharmaceutical Operations. In this newly created role, Mr. Lichter will oversee Akorn's global supply chain and plant operations. Mr. Lichter joins Akorn from Abbott Laboratories where he served in various leadership roles over 32 years most recently as Corporate Vice President, Operations, for Abbott's Established Pharmaceutical Division in Switzerland. In this role, Mr. Lichter was responsible for the division's global supply chain operations including active and finished drug product manufacturing, procurement, manufacturing, engineering, and commercial operations. Jaspreet Gill, former Vice President, Corporate Quality at Baxter, was appointed Executive Vice President, Global Quality Compliance. In her newly created role at Akorn, Ms. Gill will oversee global regulatory compliance for all Akorn manufacturing sites as well as members of Akorn's supply chain. Prior to Baxter, Ms. Gill held quality leadership roles at Johnson & Johnson and began her career at Bio-Rad Laboratories.

Akorn, Inc. Affirms Earnings Guidance for the Full Year 2015

Akorn, Inc. affirmed earnings guidance for the full year 2015. For 2015, the company affirmed adjusted EPS guidance of $1.88 to $1.98 per share.

Akorn, Inc. Appoints Terry Allison Rappuhn to its Board of Directors and Member of Audit Committee

Akorn, Inc. announced the appointment of Terry Allison Rappuhn to its Board of Directors and the Board's Audit Committee, effective immediately. In her accomplished career spanning over three decades working with and for public corporations, Ms. Rappuhn has helped rapidly growing companies build infrastructure, processes and teams during periods of transition. Ms. Rappuhn was the Chief Financial Officer of Quorum Health Group, Inc. and previously served as Vice President, Controller and Assistant Treasurer as well as Vice President of Internal Audit.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AKRX:US $43.00 USD +1.36

AKRX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Hikma Pharmaceuticals PLC 2,031 GBp -16.00
Impax Laboratories Inc $46.38 USD +1.12
Lannett Co Inc $59.52 USD +2.02
Pacira Pharmaceuticals Inc/DE $68.81 USD +0.33
Sagent Pharmaceuticals Inc $23.42 USD +0.11
View Industry Companies

Industry Analysis


Industry Average

Valuation AKRX Industry Range
Price/Earnings 100.0x
Price/Sales 7.9x
Price/Book 12.4x
Price/Cash Flow 62.0x
TEV/Sales 6.3x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AKORN INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at